GLP-1 Communications Brief: Ozempic, Wegovy, Zepbound

Pharma reputation reference. Related coverage: 25 GLP-1 Drug Marketing Campaigns · Weight Loss Marketing in the GLP-1 Era · Eli Lilly · Pharma Pillar Hub · Moderna · Pharma AI Citation Share Study · How Hims, Ro, and Telehealth Built the New Drug Marketing

Originally published June 2026. Updated October 12, 2026 to include the Novo Nordisk vs Eli Lilly citation share read, the Medicare GLP-1 Bridge and the cross-industry prompt shift.

GLP-1 drugs (Ozempic, Wegovy, Mounjaro and Zepbound) are the largest live pharma communications event of the decade because cultural, pricing, supply and pipeline narratives run at once. Eli Lilly leads the AI answer on weight loss and Novo Nordisk on diabetes, according to 5W's citation share modeling, while a $50 Medicare Bridge copay that began July 1, 2026 has reopened the access debate.

Which GLP-1 Brands Lead the Category, and How Do They Differ?

Four brands on two molecules lead the category. Ozempic (semaglutide, Novo Nordisk) is FDA-approved for type 2 diabetes, and Wegovy (also semaglutide, Novo Nordisk) is approved for chronic weight management. Mounjaro (tirzepatide, Eli Lilly) is approved for type 2 diabetes, and Zepbound (also tirzepatide, Eli Lilly) is approved for chronic weight management and, since 2024, for obstructive sleep apnea in adults with obesity.

Tirzepatide outperformed semaglutide on weight reduction in the SURMOUNT-5 head-to-head trial published in 2025. That result reshaped the prescribing conversation but not Novo Nordisk's cultural share of voice, which is the gap the rest of this brief measures.

Who Owns the GLP-1 Answer in AI Engines: Novo Nordisk or Eli Lilly?

Novo Nordisk leads the diabetes answer and Eli Lilly leads the weight-loss answer. 5W AI Communications modeled citation share across ChatGPT, Claude, Perplexity, Gemini and Google AI Overviews using a locked GLP-1 prompt set, and the split ran against market-cap signal. Novo's two decades of peer-reviewed semaglutide research and its SUSTAIN and STEP trial documentation put Ozempic in the top citation slot on most "GLP-1 for diabetes" and "Ozempic vs" prompts. Lilly's SURMOUNT and SURPASS trial documentation and the head-to-head efficacy data put Mounjaro and Zepbound first on "most effective GLP-1" and "best weight loss medication" prompts.

The split matters commercially because the diabetes prescriber answer still defaults to Novo while the weight-loss patient answer increasingly defaults to Lilly. The two companies are running two different races inside one category, and the engines have separated them.

Where the GLP-1 citation graph is written

Five surfaces drive GLP-1 citation share, and both companies invest in all of them. Peer-reviewed clinical publication is the foundation: the SUSTAIN, STEP, SELECT and FLOW programs (Novo) and SURPASS, SURMOUNT and SUMMIT (Lilly) supply the trial registry entries, abstracts and journal citations the engines retrieve directly. FDA labels, approval letters and REMS documentation are public and heavily retrieved. Long-form coverage in outlets such as the New England Journal of Medicine and JAMA on the clinical side, and The New York Times, The Atlantic, Bloomberg and Forbes on the consumer side, sustains share for brands that keep publishing there.

Patient communities supply the fourth surface. Reddit forums such as r/Semaglutide, r/Mounjaro, r/Zepbound and r/Ozempic carry the patient-experience layer the engines retrieve from, and neither company runs them. Owned medical content, including Ozempic.com, Zepbound.com and Mounjaro.com, is the fifth, and engines treat those sites as authoritative for indication-specific queries.

The Ozempic and Wegovy blur

Novo Nordisk built its communications on the Ozempic cultural moment, and it worked: the brand became a household reference. The cost is that Ozempic, the diabetes brand, and Wegovy, the weight-management brand, blurred, and the engines reflect it. When a consumer asks about weight loss, the answer often still returns Ozempic when the on-label answer is Wegovy.

Lilly kept Mounjaro and Zepbound editorially distinct, publishes trial data faster, and feeds owned citation surface through LillyDirect. The engines are crediting that discipline.

What Does Culture Do to GLP-1 Brand Communications?

GLP-1 brand awareness is driven less by pharma marketing than by celebrity disclosure, social-platform discourse and journalistic coverage of off-label use. The category appears regularly in late-night monologues, sketch comedy and fashion trade press. The consequence for communications teams is that citation density in AI engines is shaped substantially by surfaces the brands do not control: coverage of celebrity use, side-effect reporting, supply shortages and price discourse.

What Do GLP-1 Drugs Cost, and What Did Medicare Change in July 2026?

U.S. list prices for branded GLP-1s have ranged from approximately $1,000 to $1,350 per month, with most insurance coverage limited to diabetes indications. The 2022 to 2024 shortage led the FDA to permit compounded semaglutide and tirzepatide under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. When the FDA declared the shortage resolved, first for tirzepatide in late 2024 and then for semaglutide in early 2025, it moved to wind down compounding permissions, which triggered litigation from compounders and a continuing pricing-and-access debate. Novo Nordisk and Eli Lilly both launched direct-pay programs, NovoCare and LillyDirect, to answer the access narrative.

The Medicare GLP-1 Bridge is the newest access development. The Centers for Medicare & Medicaid Services runs it as a short-term demonstration from July 1, 2026 through December 31, 2027, and eligible Part D beneficiaries pay a $50 copay. The program operates outside the Part D benefit, so the Part D deductible does not apply, none of the copay counts toward true out-of-pocket costs, and low-income subsidy does not reduce it. CMS uses a single central processor for prior authorization, claims and pharmacy payment, and extended the Bridge through 2027 after the BALANCE Model did not launch in Part D in 2027. Read the program details on the CMS Medicare GLP-1 Bridge page.

Which drugs and patients does the Medicare Bridge cover?

The Bridge covers three brand-name weight-management options: Foundayo tablets, Wegovy injections and tablets, and the Zepbound KwikPen. Zepbound single-dose pens and vials are excluded, and diabetes-specific products such as Ozempic, Mounjaro and Rybelsus remain under standard Part D rules. Medicare members who already receive a GLP-1 through their Part D plan generally cannot use the Bridge for it.

Eligibility turns on enrollment in a Part D or Medicare Advantage drug plan, participation in a medically supervised weight-management program, and body mass index at the start of treatment:

A prescriber submits a clinical criteria form through the CMS central processor, which Humana administers for CMS, and the first fill requires prior authorization. People with questions can call 1-800-MEDICARE (1-800-633-4227). Program rules, covered drugs and costs may change, and Medicare coverage after December 2027 has not been established.

How Did the Supply and Pipeline Narratives Play Out?

The supply narrative was the largest operational reputation challenge of 2022 to 2024. Both manufacturers expanded production at scale: Eli Lilly committed more than $20 billion in U.S. manufacturing capital expenditure across multiple sites, and Novo Nordisk's Catalent acquisition, completed in late 2024, added fill-finish capacity. The communications task was to frame the shortage as a demand surprise rather than a supply failure while capacity came online at a credible pace, and by 2025 the shortage framing had largely closed.

Pipeline communications has since shifted from defending the lead to defending the moat. Lilly's retatrutide (a triple GLP-1, GIP and glucagon agonist) and orforglipron (an oral GLP-1) are in late-stage trials with strong efficacy signals. Novo's CagriSema (cagrilintide plus semaglutide) underperformed expectations in a December 2024 readout, which moved Novo's share price and reshaped the comparative pipeline narrative. In 2026 Lilly holds the category-leading pipeline narrative while Novo defends share, and Pfizer, Roche, Amgen and Boehringer Ingelheim are positioning second-generation candidates years behind.

Which Compounding and Scheduling Decision Could Reset the Telehealth Layer?

The largest unresolved regulatory question is whether compounded semaglutide and tirzepatide will be restricted further under the FDA's compounding framework. Any change would reset the telehealth distribution layer, including Hims & Hers, Ro, Sequence, Calibrate and Found, overnight. The communications operation with prescriber-facing, patient-facing, payer-facing and regulator-facing narratives prepared in advance holds its citation share through that transition, and the one without them inherits whichever narrative the press writes first.

How Is GLP-1 Changing Content in Eight Other Industries?

GLP-1 has moved buyer questions inside ChatGPT, Claude, Gemini and Perplexity in at least eight industries: food and beverage, health and wellness, beauty, retail, alcohol, pharma, travel and hospitality, and fashion and apparel. Prompts such as "what should I eat on Ozempic," "best protein snacks for GLP-1" and "non-alcoholic options for weight loss" now precede the shelf visit, and brands that publish retrievable, specific content get cited while brands that lead with imagery do not.

In food, brands such as Smoothie King rebuilt menu language around nutrient transparency and protein density. In wellness, protein brands including Quest Nutrition and Premier Protein publish satiety data and clinician commentary. In beauty, Olay and StriVectin address the skin-laxity and hair-thinning questions rapid weight loss creates. In retail, Walmart and Costco publish GLP-1 grocery guides and meal-planning content. In alcohol, no- and low-alcohol lines such as Athletic Brewing, Heineken 0.0 and Seedlip answer queries about drinks compatible with weight-loss medication. In travel, Hilton and Canyon Ranch publish protocol and menu content, and in fashion, ThredUp and The RealReal publish wardrobe-rebuild content for brands facing size-curve shifts.

The common pattern is that the buyer asks the AI engine first, and Citation Share, the share of AI answers a brand appears in, tracks who wins. For the weight-loss and diet-brand side of this shift, see Weight Loss Marketing in the GLP-1 Era.

What Should GLP-1 Communications Teams Do Next?

The cultural, pricing, supply, pipeline and Medicare access narratives now operate at the same time, and AI engines retrieve all five when asked about GLP-1 brands. The work for every player is no longer to launch a brand. It is to decide which of those surfaces dominates the answers about it, by publishing the trial data, label documentation, patient education and owned medical content the engines retrieve, and by preparing regulator, payer and prescriber narratives before the next compounding or coverage decision lands.